Oruka Therapeutics, Inc.
ORKA
$111.04
$2.922.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 57.76% | 41.23% | 41.04% | 36.16% | 53.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.25% | 45.24% | 13.57% | 15.81% | 32.27% |
| Operating Income | -76.25% | -45.24% | -13.57% | -15.81% | -32.27% |
| Income Before Tax | -67.68% | -51.53% | -14.75% | -5.78% | -10.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.68% | -51.53% | -14.75% | -5.78% | -10.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.68% | -51.53% | -14.75% | -5.78% | -10.48% |
| EBIT | -76.25% | -45.24% | -13.57% | -15.81% | -32.27% |
| EBITDA | -76.22% | -45.16% | -13.54% | -15.76% | -- |
| EPS Basic | -20.80% | -20.84% | 7.87% | 62.66% | 93.40% |
| Normalized Basic EPS | -12.25% | -14.48% | 15.37% | 63.96% | 91.61% |
| EPS Diluted | -20.80% | -20.84% | 7.87% | 62.66% | 93.40% |
| Normalized Diluted EPS | -12.25% | -14.48% | 15.37% | 63.96% | 91.61% |
| Average Basic Shares Outstanding | 49.35% | 32.37% | 35.60% | 193.51% | 1,216.32% |
| Average Diluted Shares Outstanding | 49.35% | 32.37% | 35.60% | 193.51% | 1,216.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |